Take One: Big story of the day
-
Inside India's Covid-19 vaccine trials: The volunteers' story
Volunteers who took the jab give Forbes India a peek into their apprehensions and the aftermath
-
Testing company Kilpest: Valuing a sudden bump in profitability
An unexpected and extraordinary development at Kilpest left investors grappling with a question: How does one value an extraordinary surge in profits?
-
Farm acts: Are the reforms necessary?
Ahead of the farmer-led Bharat Bandh tomorrow, we speak to farmers on-ground to understand the way forward, and why they will continue to stand their ground
-
Covid-19 vaccine trials: How much information is too much information?
As the Serum Institute moves towards seeking emergency-use authorisation of its vaccine candidate, experts talk about navigating the grey area of deciding how much information around the clinical trials needs to be made public in order to retain people's trust in the process
-
We can be 100% transparent with Covid-19 trials, but that will have very low utility value: Dr Gagandeep Kang
The virologist and fellow of the Royal Society of London speaks to Forbes India about transparency in clinical trials, emergency use authorisation for a Covid-19 vaccine candidate in India and whether the vaccine should be available for sale in the private market. Edited excerpts
-
Mahashay Dharampal Gulati: How a horse-cart driver became India's spice king with MDH
A man ahead of his time, the ever-smiling nonagenarian who passed away on Thursday, built an enviable brand and ended up becoming the highest-paid CEO in the FMCG sector in India in 2017
-
Can digital insurance startup Acko disrupt the complex sector?
The startup has galloped at a lightning pace since it started operations in January 2018. But what it is attempting isn't easy
-
Freshly minted unicorn Cars24 steps on the gas
Cars24, India's first unicorn in the auto segment, has grown rapidly during the pandemic. Can it maintain its pace and focus?
-
What ails India's financial system?
The Reserve Bank of India is on an overdrive to stem asset quality rot in the banking system, although now may not be the time for 'big-bang reform' like allowing private corporations into the lending business
-
Big story: How will India vaccinate 1.3 billion people?
India is a powerhouse when it comes to vaccine manufacturing, but the focus is now on addressing the complexities in storing and distributing the Covid-19 vaccines
-
LVB-DBIL merger: A stern message to weak banks
The amalgamation augurs well for both banks despite the challenges. With it, the government and Reserve Bank of India have made it clear that interests of depositors and banking stability are of prime importance